Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 114,108 shares at $2.85 ($325K) on 2025-08-21, disclosed to the SEC on 2025-08-22.
Open-market sale of $325k TSHA by President and Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.85 | 57,054 | $163K | 50.0% |
| 2 | $2.85 | 57,054 | $163K | 50.0% |
| Total | $2.85 avg | 114,108 | $325K | 100% |
| Filing → |
| TSHA | SELL | 2026-01-27 | $547K | — | Filing → |
| TSHA | SELL | 2026-01-14 | $942K | — | Filing → |
| TSHA | SELL | 2025-12-01 | $3.4M | — | Filing → |